Analyst Price Targets — XGN
| Date | Analyst | Firm | Target | Price @ Post | Source | Headline |
|---|---|---|---|---|---|---|
| April 20, 2026 1:10 pm | — | Canaccord Genuity | $8.00 | $2.97 | TheFly | Exagen price target lowered to $8 from $10 at Canaccord |
| March 11, 2026 1:15 pm | — | UBS | $10.00 | $3.11 | TheFly | Exagen price target lowered to $10 from $12 at Craig-Hallum |
| March 10, 2026 7:38 pm | Mark Massaro | BTIG | $9.00 | $3.25 | StreetInsider | Exagen (XGN) PT Lowered to $9 at BTIG |
| February 17, 2026 12:15 pm | Mark Massaro | BTIG | $10.00 | $3.28 | TheFly | Exagen price target lowered to $10 from $15 at BTIG |
| October 27, 2025 10:50 am | — | Canaccord Genuity | $15.00 | $11.96 | TheFly | Exagen price target raised to $15 from $11 at Canaccord |
| October 14, 2025 10:36 am | — | KeyBanc | $15.00 | $11.04 | TheFly | Exagen price target raised to $15 from $12 at KeyBanc |
| July 30, 2025 12:55 pm | — | Cantor Fitzgerald | $10.00 | $8.63 | TheFly | Exagen price target raised to $10 from $7 at Cantor Fitzgerald |
| July 29, 2025 11:28 pm | — | KeyBanc | $12.00 | $8.45 | TheFly | Exagen upgraded to Overweight from Sector Weight at KeyBanc |
| November 12, 2024 9:06 pm | Mark Massaro | BTIG | $5.00 | $2.79 | StreetInsider | BTIG Reiterates Buy Rating on Exagen (XGN) |
| May 14, 2024 8:00 am | Kyle Mikson | Canaccord Genuity | $5.00 | $1.64 | StreetInsider | Canaccord Genuity Reiterates Buy Rating on Exagen (XGN) |
Latest News for XGN
Exagen Inc. (XGN) Q4 2025 Earnings Call Transcript
Exagen Inc. (XGN) came out with a quarterly loss of $0.2 per share in line with the Zacks Consensus Estimate. This compares to a loss of $0.2 per share a year ago.
Record full-year total revenue and AVISE® CTD average selling price New biomarkers and sales force expansion drove over 11% full-year test volume growth CARLSBAD, Calif., March 10, 2026 (GLOBE NEWSWIRE) -- Exagen Inc. (Nasdaq: XGN), a leading provider of autoimmune testing, today reported financial results for the fourth quarter and full year ended December 31, 2025, and recent business highlights.
Exagen Inc. (NASDAQ: XGN - Get Free Report) has earned a consensus rating of "Moderate Buy" from the ten research firms that are presently covering the company, MarketBeat Ratings reports. One analyst has rated the stock with a sell rating and nine have given a buy rating to the company. The average 12-month price objective among
CARLSBAD, Calif., March 03, 2026 (GLOBE NEWSWIRE) -- Exagen Inc. (Nasdaq: XGN), a leading provider of autoimmune testing, today announced that management will participate in the following investor conferences: KeyBank Capital Markets Healthcare Forum - Virtual Date: March 17, 2026 Participation: Investor meetings and fireside chat at 3:00 p.m.
🧮 Earnings Move Analyzer
Insider Trading
Insider Trading
| Name | Role | Date | Type | Shares | Price | Form | Link |
|---|
Senate Trading
No Senate trades found for XGN.
U.S. House Trading
No House trades found for XGN.
Options Chain
Select an expiration to expand. Bid/Ask are shown first (before Mark) on both sides.